The number of Coronavirus-infected people is constantly increasing. This article gives an insight into the impact of the infection:
–
–
–
–
While in the world possible means against the pathogen, SARS-CoV2 are developed and tested research, German scientists, in addition to a new transport technology to facilitate the implementation of vaccination.
The Max-Planck-Institute for colloid and interface research (MPIKG) in Potsdam and the Lead Discovery Center (LDC) in Dortmund, which wants to implement medical research in effective treatments, plan a COVID-19 vaccine directly to the skin, leave on for – alternatively, the micro-needles can be used. Potentially painful in the muscles injected, the vaccine would not have to be, as regular vaccinations.
Faster Immune Response
However, the pain-free vaccination would be a more desirable welcome side-effect. The idea is rather attractive because the immune cells density in the skin by the so-called Langerhans cells is the highest. The activation of the immune system leads, in combination with a Glycomimetikum to a particularly efficient release of the vaccine. This is a sugar-similar component, which has been chemically modified so that it has a higher affinity and, above all, specificity for the Receptor events changed. The new transport technology would stimulate the body’s own immune system so in a more targeted and lead to an accelerated, anti-viral response.
–
(Image: Langerhans cell research laboratory at the Medical University of Innsbruck)
The research group at the Max-Planck-Institute is headed by Dr. Christoph Rademacher, who invented the technology. “We assume that our System can put all the vaccines freely, the proteins, peptides or mRNA use,” he says. In the process, there is a new platform technology that could be used far from only against COVID-19.
Vaccine development in full swing
Is financed with the cooperation of the two institutes from the resources of the technology transfer Fund, KHAN I. The Fund made it possible, according to managing Director Bert Klebl is a “first step”, however, more investors are “welcome”. The Spin-off for commercialization, already has a name: Cutanos GmbH. The research of new transportation technology, however, is expected to take some time – in the worst case, it could take a few more years.
–
(Image: Photo by Tedward Quinn on Unsplash)
Currently, numerous groups of Scientists working around the world of medications or vaccines against the new Coronavirus. It is currently assumed that only a vaccination of the population can say to combat SARS-CoV2 sustainable. The world health organization, WHO, is now one of at least 118 research projects that deal with the development of a vaccine against COVID-19. Regardless of which group is to develop the most promising vaccine the fastest way: Through the collaboration of the Max-Planck-Institute in Potsdam and the Lead Discovery Center in Dortmund, is a more efficient technology could be ready to have the vaccination administered. Afraid of needles, you need to have no more.
(bsc)
– .
